Literature DB >> 10191177

Hypermutability and silent mutations in human carcinogenesis.

B S Strauss1.   

Abstract

Silent or synonymous mutations are nucleotide changes which do not result in an amino acid change. Such alterations make up approximately 4% of the total TP53 mutations in a database of almost 10,000 mutations. Insofar as these changes do not confer a selective advantage, silent mutations make it possible to estimate an unbiased mutation frequency. Since this frequency is at least 100 times higher than would be expected for normal tissue, tumors must be hypermutable. In addition, a class of tumors may be supermutable with a mutation frequency comparable to that observed in the generation of immune diversity. Copyright 1998 Academic Press.

Entities:  

Mesh:

Year:  1998        PMID: 10191177     DOI: 10.1006/scbi.1998.0092

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  6 in total

1.  Redundancy, antiredundancy, and the robustness of genomes.

Authors:  David C Krakauer; Joshua B Plotkin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

Review 2.  Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential.

Authors:  Brigid S Mumford; Gavin P Robertson
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

Review 3.  Metastasis: recent discoveries and novel treatment strategies.

Authors:  Suzanne A Eccles; Danny R Welch
Journal:  Lancet       Date:  2007-05-19       Impact factor: 79.321

Review 4.  Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146.

Authors:  Maria Cristina Rapanotti; Elena Campione; Giulia Spallone; Augusto Orlandi; Sergio Bernardini; Luca Bianchi
Journal:  Cell Death Discov       Date:  2017-03-06

5.  Clonal mutations in primary human glial tumors: evidence in support of the mutator hypothesis.

Authors:  Anjan Misra; Parthaprasad Chattopadhyay; Kunzang Chosdol; Chitra Sarkar; Ashok K Mahapatra; Subrata Sinha
Journal:  BMC Cancer       Date:  2007-10-09       Impact factor: 4.430

6.  Radiomic features of primary tumor by lung cancer stage: analysis in BRAF mutated non-small cell lung cancer.

Authors:  Atul Padole; Ramandeep Singh; Eric W Zhang; Dexter P Mendoza; Ibiayi Dagogo-Jack; Mannudeep K Kalra; Subba R Digumarthy
Journal:  Transl Lung Cancer Res       Date:  2020-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.